US · Healthcare · Biotechnology
EPS came in at -1.69 against a street estimate of -1.37 — a miss of 23.4%.
Analysts rate Vera Therapeutics Inc a strong buy (13 buy, 1 hold, 0 sell out of 14) with an average price target of $81.79.
| Fund | Stake |
|---|---|
| venBio Select Advisor LLC | 8.21% |
| BlackRock Inc | 7.09% |
| T. Rowe Price Associates, Inc. | 6.38% |
| Deep Track Capital, LP | 5.73% |
| Deerfield Management Co | 5.19% |
| Kynam Capital Management, LP | 4.74% |
| State Street Corp | 4.69% |
| Sofinnova Ventures | 3.90% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 | 2026-07-09 |
| Company announcement · Q3 2026 | 2026-07-07 |
| Company announcement · Q2 2026 | 2026-06-02 |
| Shareholder vote results · Q2 2026 | 2026-05-26 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Proxy statement · Q2 2026 | 2026-04-09 |
| Annual report FY2025 | 2026-02-26 |
| Quarterly report · Q3 2025 | 2025-11-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Vera Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.